Ramosetron


Generic Medicine Info
Indications and Dosage
Intravenous
Nausea and vomiting associated with cancer chemotherapy
Adult: 300 mcg once daily. May administer an additional dose of 300 mcg if necessary. Max: 600 mcg/day.

Oral
Nausea and vomiting associated with cancer chemotherapy
Adult: 100 mcg once daily.

Oral
Irritable bowel syndrome in men
Adult: 5 mcg once daily, may adjust dose according to symptoms. Max: 10 mcg/day.
Administration
May be taken with or without food.
Incompatibility
D-mannitol inj, bumetanide inj and furosemide inj.
Special Precautions
Elderly; Pregnancy. Not recommended in lactation. Safety and efficacy in paediatric population has not been established.
Adverse Reactions
Headache, diarrhoea, constipation, rash, itching, redness, heat, hot flushes, hiccup, numbness of tongue, hepatic dysfunction (increased AST, ALT, GPT, and bilirubin), increased BUN. Epileptiform attacks have been reported with other 5-HT3 antagonists.
Potentially Fatal: Shock or anaphylactoid symptoms may occur.
Drug Interactions
May increase plasma concentration when given with fluvoxamine (CYP1A2 inhibitor).
Action
Description: Ramosetron is a 5-HT3 receptor antagonist. It exerts its antiemetic property by blocking of serotonin to 5-HT3 receptors present in the afferent vagal nerve-endings in the GI mucosa.
Pharmacokinetics:
Metabolism: Hepatic metabolism mainly via CYP1A2 and CYP2D6 enzymes.
Excretion: Excreted in urine as unchanged drug (16-22% within 24 hr following IV admin), demethylated and hydroxylated metabolites and their conjugates. βphase elimination half-life: About 5 hr.
Storage
Intravenous:
Store in light-proof containers at room temperature.
Disclaimer: This information is independently developed by MIMS based on Ramosetron from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in